DE60110912D1 - Valproinsäure und deren derivate als histondeacetylaseinhibitoren - Google Patents

Valproinsäure und deren derivate als histondeacetylaseinhibitoren

Info

Publication number
DE60110912D1
DE60110912D1 DE60110912T DE60110912T DE60110912D1 DE 60110912 D1 DE60110912 D1 DE 60110912D1 DE 60110912 T DE60110912 T DE 60110912T DE 60110912 T DE60110912 T DE 60110912T DE 60110912 D1 DE60110912 D1 DE 60110912D1
Authority
DE
Germany
Prior art keywords
valproic acid
derivatives
histone
histondeacetylaseinhibitors
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60110912T
Other languages
English (en)
Other versions
DE60110912T2 (de
Inventor
Martin Goettlicher
Thorsten Heinzel
Bernd Groner
Peter Herrlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Original Assignee
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Publication of DE60110912D1 publication Critical patent/DE60110912D1/de
Application granted granted Critical
Publication of DE60110912T2 publication Critical patent/DE60110912T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60110912T 2000-07-07 2001-07-05 Valproinsäure und deren derivate als histondeacetylaseinhibitoren Expired - Lifetime DE60110912T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00114088A EP1170008A1 (de) 2000-07-07 2000-07-07 Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
EP00114088 2000-07-07
PCT/EP2001/007704 WO2002007722A2 (en) 2000-07-07 2001-07-05 Valproic acid and derivatives thereof as histone deacetylase inhibitors

Publications (2)

Publication Number Publication Date
DE60110912D1 true DE60110912D1 (de) 2005-06-23
DE60110912T2 DE60110912T2 (de) 2005-10-20

Family

ID=8169134

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60110912T Expired - Lifetime DE60110912T2 (de) 2000-07-07 2001-07-05 Valproinsäure und deren derivate als histondeacetylaseinhibitoren

Country Status (10)

Country Link
US (2) US7265154B2 (de)
EP (2) EP1170008A1 (de)
JP (1) JP2004504347A (de)
AT (1) ATE295725T1 (de)
AU (2) AU2001283925B2 (de)
CA (1) CA2414967C (de)
DE (1) DE60110912T2 (de)
ES (1) ES2239677T3 (de)
PT (1) PT1301184E (de)
WO (1) WO2002007722A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1170008A1 (de) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2003018767A2 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
EP1293205A1 (de) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproinsäure und deren Derivate zur Kombinationsbehandlung von Krebs beim Menschen und zur Behandlung von Tumor-Metastasen und minimaler Resterkrankung
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
WO2003032921A2 (en) 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
CA2478479A1 (en) 2002-03-07 2003-09-18 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phagebeta protein, or hydroxyurea
IL149404A0 (en) * 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US20060247192A1 (en) * 2002-12-05 2006-11-02 Jenkinson John D Control of apoptosis
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
CA2518318A1 (en) * 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
PT1591109E (pt) * 2004-04-30 2008-09-05 Desitin Arzneimittel Gmbh Formulação exibindo libertação bifásica compreendendo um inibidor da desacetilase de histona
KR100659779B1 (ko) 2004-09-04 2006-12-19 주식회사 바이넥스 히스톤 디아세틸라제 억제제를 함유하는 중간엽줄기세포의 골분화유도용 조성물 및 이를 이용한 골분화증가방법
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006270322A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2008011603A2 (en) * 2006-07-20 2008-01-24 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
US20080085874A1 (en) * 2006-08-28 2008-04-10 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
CA2671649A1 (en) * 2006-12-06 2008-06-12 Sapporo Medical University Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
WO2009079375A1 (en) * 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
US8623853B2 (en) 2008-07-23 2014-01-07 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the NUT gene
ES2473792T3 (es) 2009-04-03 2014-07-07 Naturewise Biotech & Medicals Corporation Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
US7994357B2 (en) 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2277387B1 (de) 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation Neue verwendung von histon-deacetylaseinhibitoren in veränderlichem mrjp3-protein in gelée royale
EP2475769B1 (de) * 2009-09-07 2016-11-09 Jawaharlal Nehru Centre for Advanced Scientific Research Hemmung von histonacetyltransferasen durch ctk7a und verfahren dafür
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
EP3470536A1 (de) 2013-10-01 2019-04-17 The J. David Gladstone Institutes Zusammensetzungen, systeme und verfahren zum wirkstoffscreening auf genexpressionsrauschen und verwendungen davon
AU2015252844A1 (en) * 2014-05-02 2016-11-03 Kay NOEL Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
CN105622712B (zh) * 2014-10-27 2019-08-27 天津金耀集团有限公司 一种甾体3-酮-4-烯物合成工艺
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3863648A1 (de) * 2018-10-12 2021-08-18 Life Technologies Corporation Expansionssystem für hämatopoietische stamm- und vorläuferzellen
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672746A (en) * 1994-08-30 1997-09-30 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US6300373B1 (en) * 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
EP1736152A3 (de) * 1993-10-29 2009-10-07 The Trustees Of Boston University Physiologisch stabile Butlersäurepräparate, und Butlersäuresalze und Derivate zur Behandlung von Wunden
CA2231251A1 (en) * 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO1997047307A1 (en) * 1996-06-14 1997-12-18 The Uab Research Foundation Use of histone deacetylase inhibitors to activate transgene expression
EP0961614A4 (de) * 1996-12-30 2002-07-24 Univ Bar Ilan Oxyalkylester die tricarboxylsaeuren enthalten und deren verwendung
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AU1395999A (en) * 1997-11-10 1999-05-31 Salk Institute For Biological Studies, The Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
EP1170008A1 (de) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase

Also Published As

Publication number Publication date
JP2004504347A (ja) 2004-02-12
US7265154B2 (en) 2007-09-04
US20040087652A1 (en) 2004-05-06
WO2002007722A3 (en) 2002-07-18
EP1170008A1 (de) 2002-01-09
EP1301184B1 (de) 2005-05-18
US20070232696A1 (en) 2007-10-04
EP1301184A2 (de) 2003-04-16
ES2239677T3 (es) 2005-10-01
CA2414967C (en) 2009-08-25
ATE295725T1 (de) 2005-06-15
DE60110912T2 (de) 2005-10-20
AU8392501A (en) 2002-02-05
PT1301184E (pt) 2005-07-29
AU2001283925B2 (en) 2005-07-14
CA2414967A1 (en) 2002-01-31
WO2002007722A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
DE60110912D1 (de) Valproinsäure und deren derivate als histondeacetylaseinhibitoren
CY1119148T1 (el) Φαρμακευτικες συνθεσεις και συναφεις μεθοδοι χορηγησης
ATE408601T1 (de) Fredericamycin-derivate
CY1109551T1 (el) Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
CY1118363T1 (el) Αντισωματα που ανοσοειδικως συνδεονται προς blys
CY1116314T1 (el) Συνθεσεις που περιεχουν ορνιθινη και οξικο φαινυλεστερα ή βουτυρικο φαινυλεστερα για τη θεραπεια της ηπατικης εγκεφαλοπαθειας
EA200401365A1 (ru) Способы лечения илеуса
CY1110405T1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
ATE441628T1 (de) Tricyclische hydroxamat- und benzamidderivate, zusammensetzungen und verfahren
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
EA200501570A1 (ru) Новые гидроксаматы как лечебные средства
CY1106601T1 (el) Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
NO20045056L (no) Fremgangsmater for behandling av hepatitt
NO20030724L (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
EA200500782A1 (ru) Лечение геморрагического шока
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
DE60317098D1 (de) Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
CY1111899T1 (el) Καινοφανη παραγωγα πυρρολης με δραστηριοτητα αναστολεα της απακετυλασης της ιστονης
DE60026046D1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition